Hyperfractioned Regional Nodal Irradiation for women with invasive breast cancer

Trial ID:
IRB-22-7881
Ray Lin, M.D.
This study will test the safety and effectiveness of regional-nodal irradiation given over 3 weeks compared to the standard of 5 weeks.
*Be 18 years or older <br>*Have pathologically confirmed invasive breast cancer<br>*Prior mastectomy or lumpectomy with axillary evaluation

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org